Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients
BioCentury - Roche in $350M deal with Sommadossi's Atea for what it believes could be first oral COVID-19 antiviral
![Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.] Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]](https://uspto.report/patent/app/20200331956/US20200331956A1-20201022-C00001.png)
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]
Jean Sommadossi - Founder & Chief Executive Officer @ Idenix Pharmaceuticals - Crunchbase Person Profile
![Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.] Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substi- Tuted Purine Nucleotides For Hcv Treatment Sommadossi; Jean-Pierre ; et al. [Atea Pharmaceuticals, Inc.]](https://uspto.report/patent/app/20200331956/US20200331956A1-20201022-C00002.png)